NDOR1

NDOR1 (NADPH-dependent diflavin oxidoreductase 1), also known as Cyb5R3 or NR1, functions as an electron transferase bridging cellular redox systems and iron metabolism. This flavoprotein facilitates heme biosynthesis by reducing cytochrome b5, a critical step in hemoglobin synthesis and drug metabolism. Its interaction with cytochrome P450 enzymes links it to xenobiotic detoxification, while dysregulation contributes to congenital methemoglobinemia and neurodegenerative disorders like Parkinson's disease. Recent studies implicate NDOR1 deficiency in impaired erythrocyte maturation and pathological iron accumulation in dopaminergic neurons.
Therapeutic exploration remains nascent, though NDOR1's role in stabilizing hypoxia-inducible factors has spurred interest in oncology. Small-molecule activators targeting its FAD-binding domain show preclinical efficacy in alleviating anemia of chronic disease. Conversely, NDOR1 inhibitors are being evaluated for sensitizing ferroptosis-resistant tumors to chemotherapy. No clinical candidates have emerged, but CRISPR-based screening highlights its synthetic lethality with BRCA1 mutations, suggesting potential for precision therapy in breast cancer.

Popular Product:

Recombinant Human NADPH-dependent diflavin oxidoreductase 1 (NDOR1)